What is Varicella Live Vaccine Market?
According to the Centers for Disease Control and Prevention, every year more than 3.5 million cases of varicella, around 9,000 hospitalizations, and 100 deaths are prevented by varicella vaccination in the United States. DiseaseVaricella, also known as chickenpox, is an acute and highly contagious disease caused by primary infection with the varicella-zoster virus (VZV). Varicella live vaccine contains a live strain of the varicella-zoster (chickenpox) virus which has been weakened (attenuated) that helps to stimulate the immune system but does not cause infection in healthy people. This vaccine is recommended for those people who are in close contact with people who are particularly at risk of complications from chickenpox.
The market study is being classified by Type (Single-antigen Vaccine and Combined Vaccine), by Application (Chickenpox Immunization, Herpes Zoster Immunization and MMRV Immunization) and major geographies with country level break-up.
Bio-Med Pvt. Limited (India), Changchun BCHT Biotechnology Co. Ltd. (China), Emcure Pharmaceuticals Limited (India), GlaxoSmithKline plc (United Kingdom), Green Cross Holdings (South Korea), Merck & Co. Inc. (United States), Mitsubishi Chemical Holdings Corporation (Japan), Novo Medi Sciences Pvt. Ltd. (India), Sanofi S.A. (France) and Takeda Pharmaceutical Company Limited. (Japan) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that Indian Players will contribute to the maximum growth of Global Varicella Live Vaccine market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Varicella Live Vaccine market by Type, Application and Region.
On the basis of geography, the market of Varicella Live Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Funding for Immunization Programs by Various Governments Worldwide
- Increased Awareness about Varicella
- High Demand for Combination Vaccine
- Side Effects of the Varicella Live Vaccine
- Growth in the Healthcare Sector Worldwide
- Increased Research and Development Activities
- Stringent Government Rules and Regulations for Vaccine Approval
In May 2019, GlaxoSmithKline plc has announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or older. Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
Key Target AudienceVaricella Live Vaccine Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase